Citadel Advisors
CRXT

Citadel Advisors’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Citadel Advisors’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,597
Closed -$31K – 15132
2021
Q4 		$31K Buy
+12,597
New +$54.7K ﹤0.01% 13475

Other funds holding CRXT

BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Citadel Advisors's CRXT Position: Q1 2022 in Review

Citadel Advisors sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q1 2022, closing a stake of 12,597 shares — an estimated $31K sold.

Citadel Advisors first reported a position in CRXT in Q4 2021 and held it in 1 quarter. The position peaked at $31K in Q4 2021. 13 funds tracked by Wall St. Rank hold CRXT as of Q1 2022.

  • Citadel Advisors reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Citadel Advisors sold 12,597 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q1 2022, an estimated $31K.
  • Citadel Advisors first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Citadel Advisors's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $31K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on Citadel Advisors's 13F filing for Q1 2022, filed 16 May 2022.